INDIANAPOLIS, Jan. 30, 2013 /PRNewswire/ --
-- Fourth-quarter 2013 revenue declined 2 percent driven by Cymbalta U.S. patent expiration, partially offset by growth in other products.
-- Fourth-quarter 2013 earnings per share were $0.67 (reported), or $0.74 (non-GAAP).
Help employers find you! Check out all the jobs and post your resume.
